RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase 3 Randomized, Placebo-Controlled Trial
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 3
SP 11
OP 11
DO 10.1177/155989770700700303
UL http://mdc.sagepub.com/content/7/3/11.abstract
AB The Sorafenib HCC Assessment Randomized Protocol [SHARP] trial demonstrated that treatment with sorafenib prolonged overall survival by 44% and prolonged time to progression by 73% for patients with advanced hepatocellular carcinoma.